Once-Weekly Insulin Icodec in Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Clinical Trials (ONWARDS Clinical Program).

Autor:	Lisco G; Interdisciplinary Department of Medicine, School of Medicine, University of Bari 'Aldo Moro', Piazza Giulio Cesare 11, 70124 Bari, Italy., De Tullio A; Interdisciplinary Department of Medicine, School of Medicine, University of Bari 'Aldo Moro', Piazza Giulio Cesare 11, 70124 Bari, Italy., De Geronimo V; Unit of Endocrinology, Policlinico Morgagni CCD, 95125 Catania, Italy., Giagulli VA; Interdisciplinary Department of Medicine, School of Medicine, University of Bari 'Aldo Moro', Piazza Giulio Cesare 11, 70124 Bari, Italy., Guastamacchia E; Interdisciplinary Department of Medicine, School of Medicine, University of Bari 'Aldo Moro', Piazza Giulio Cesare 11, 70124 Bari, Italy., Piazzolla G; Interdisciplinary Department of Medicine, School of Medicine, University of Bari 'Aldo Moro', Piazza Giulio Cesare 11, 70124 Bari, Italy., Disoteo OE; Unit of Endocrinology, Diabetology, Dietetics and Clinical Nutrition, Sant Anna Hospital, San Fermo della Battaglia, 22020 Como, Italy., Triggiani V; Interdisciplinary Department of Medicine, School of Medicine, University of Bari 'Aldo Moro', Piazza Giulio Cesare 11, 70124 Bari, Italy.
Jazyk:	angličtina
Zdroj:	Biomedicines [Biomedicines] 2024 Aug 14; Vol. 12 (8). Date of Electronic Publication: 2024 Aug 14.
DOI:	10.3390/biomedicines12081852
Abstrakt:	Background: One hundred years have passed since the discovery of insulin, which is one of the most relevant events of the 20th century. This period resulted in extraordinary progress in the development of novel molecules to improve glucose control, simplify the insulin regimen, and ameliorate the quality of life. In late March 2024, the first once-weekly basal analog Icodec was approved for diabetes mellitus, generating high expectations. Our aim was to systematically review and meta-analyze the efficacy and safety of Icodec compared to once-daily insulin analogs in type 1 (T1D) and type 2 diabetes (T2D). Methods: PubMed/MEDLINE, Cochrane Library, and ClinicalTrials.gov were searched for randomized clinical trials (RCTs). Studies were included for the synthesis according to the following prespecified inclusion criteria: uncontrolled T1D or T2D, age ≥ 18 years, insulin Icodec vs. active comparators (Degludec U100, Glargine U100, Glargine U300, and Detemir), phase 3, multicenter, double-blind or open-label RCTs, and a study duration ≥ 24 weeks. Results: The systematic review included 4347 patients with T1D and T2D inadequately controlled (2172 randomized to Icodec vs. 2175 randomized to once-daily basal analogs). Icodec, compared to once-daily basal analogs, slightly reduced the levels of glycated hemoglobin (HbA1c) with an estimated treatment difference (ETD) of -0.14% [95%CI -0.25; -0.03], p = 0.01, and I 2 68%. Patients randomized to Icodec compared to those on once-daily basal analogs had a greater probability to achieve HbA1c < 7% without clinically relevant or severe hypoglycemic events in 12 weeks from randomization with an estimated risk ratio (ERR) of 1.17, [95%CI 1.01, 1.36], p = 0.03, and I 2 66%. We did not find a difference in fasting glucose levels, time in range, and time above range between Icodec and comparators. Icodec, compared to once-daily basal analogs, resulted in a slight but statistically significant weight gain of 0.62 kg [95%CI 0.25; 0.99], p = 0.001, and I 2 25%. The frequency of hypoglycemic events (ERR 1.16 [95%CI 0.95; 1.41]), adverse events (ERR 1.04 [95%CI 1.00; 1.08]), injection-site reactions (ERR 1.08 [95%CI 0.62; 1.90]), and the discontinuation of treatments were similar between the two groups. Icodec was found to work better when used in a basal-only than basal-bolus regimen with an ETD in HbA1c of -0.22%, a probability of achieving glucose control of +33%, a probability of achieving glucose control without clinically relevant or severe hypoglycemia of +28%, more time spent in target (+4.55%) and less time spent in hyperglycemia (-5.14%). The risk of clinically relevant or severe hypoglycemic events was significantly higher when background glinides and sulfonylureas were added to basal analogs (ERR 1.42 [95%CI 1.05; 1.93]). Conclusion: Insulin Icodec is substantially non-inferior to once-daily insulin analogs in T2D, either insulin-naïve or insulin-treated. However, Icodec works slightly better than competitors when used in a basal-only rather than basal-bolus regimen. Weight gain and hypoglycemic risk are substantially low but not negligible. Patients' education, adequate lifestyle and pharmacological interventions, and appropriate therapy adjustments are essential to minimize risks. This systematic review is registered as PROSPERO CRD42024568680.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu